Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 3/20 | 0.53 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.53 |
| ▸ | AKT1 | P31749 | 1/20 | 0.47 |
| ▸ | NAMPT | P43490 | 7/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | CCR3 | P51677 | 1/20 | 0.44 |
| ▸ | PRKD1 | Q15139 | 2/20 | 0.40 |
| ▸ | ACHE | P22303 | 2/20 | 0.40 |
| ▸ | BACE1 | P56817 | 2/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3318786 | 0.89 | ROCK1 (0.45) | ROCK1ROCK2NAMPTCCR3DYRK1A | |
| SCHEMBL3315981 | 0.85 | ROCK2 (0.52) | ROCK1ROCK2NAMPTCCR3ACHE | |
| SCHEMBL3313713 | 0.85 | CCR3 (0.46) | ROCK1ROCK2CCR3ACHEBACE1 | |
| SCHEMBL3311418 | 0.84 | CCR3 (0.43) | ROCK1ROCK2NAMPTCCR3ACHE | |
| SCHEMBL3313446 | 0.83 | ROCK2 (0.45) | ROCK1ROCK2CCR3ACHEBACE1 | |
| SCHEMBL3312007 | 0.82 | ROCK2 (0.61) | ROCK1ROCK2AKT1NAMPTPRKD1 | |
| SCHEMBL3317311 | 0.82 | ACHE (0.59) | ROCK1ROCK2CCR3ACHEBACE1 | |
| SCHEMBL3314072 | 0.80 | CCR3 (0.45) | CCR3ACHEBACE1GSK3BDYRK1A | |
| SCHEMBL3316792 | 0.78 | ROCK2 (0.54) | ROCK1ROCK2AKT1NAMPTPRKD1 | |
| SCHEMBL3316796 | 0.78 | ROCK2 (0.54) | ROCK1ROCK2AKT1NAMPTPRKD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8748614-B2 | Substituted isoquinoline and isoquinolinone derivatives | SANOFI (FR) | 2014-06-10 | — | — | US | disclosed |
| US-20100105650-A1 | Substituted isoquinoline and isoquinolinone derivatives | SANOFI-AVENTIS (FR) | 2010-04-29 | — | — | US | disclosed |
| EP-2114920-A1 | SUBSTITUTED ISOQUINOLINE AND ISOQUINOLINONE DERIVATIVES | Sanofi-Aventis (FR) | 2009-11-11 | — | — | EP | disclosed |
| WO-2008077552-A1 | SUBSTITUTED ISOQUINOLINE AND ISOQUINOLINONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105650-A1 | Substituted isoquinoline and isoquinolinone derivatives | MYLK2, MYLK, MYLK3 | ROCK1 5/4885ROCK2 6/4885AKT1 124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.